PascalFr.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « PascalFr.i » - entrée « Catécholamine »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Catostomus commersoni < Catécholamine < Catégorie socioprofessionnelle  Facettes :

List of bibliographic references indexed by Catécholamine

Number of relevant bibliographic references: 19.
Ident.Authors (with country if any)Title
002E27 (2003) Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
002E89 (2003) C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis]A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
002F48 (2003) Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
003325 (2001) André Parent [Canada] ; Martine Cossette [Canada]Extrastriatal dopamine and Parkinson's disease
003335 (2001) Oleh Hornykiewicz [Autriche]Dopamine and Parkinson's disease: A personal view of the past, the present, and the future
003351 (2001) Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover
003553 (2000) Hong Y. Choi [Canada] ; Jin H. Song [Canada] ; Dong K. Park [Corée du Sud] ; Gregory M. Ross [Canada]The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics
003554 (2000) James N. Oak [Canada] ; John Oldenhof [Canada] ; Hubert H. M. Van Tol [Canada]The dopamine D4 receptor : one decade of research
003797 (1999) Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis]Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys
003803 (1999) Nicolaas Paul L. G. Verhoeff [Canada]Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
003829 (1999) R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
003946 (1998) Ali Samii [Canada] ; Shallen R. Letwin [Canada] ; Donald B. Calne [Canada]Prospects for new drug treatment in idiopathic parkinsonism
003B97 (1997) Chien-Tsai Lai [Canada] ; Peter H. Yu [Canada]Dopamine- and l-β-3,4-dihydroxyphenylalanine hydrochloriDe (l-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y Cells
003C54 (1997) C. Thiffault [Canada] ; L. Lamarre-Theroux [Canada] ; R. Quirion [Canada] ; J. Poirier [Canada]L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse
004662 (1992) S. J. Kish [Canada] ; K. Shannak ; A. Rajput ; J. H. N. Deck ; O. HornykiewiczAging produces a specific pattern of striatal dopamine loss : implications for the etiology of idopathic Parkinson's disease
004993 (1990) M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. CalneIntracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism
004B35 (1989) C. Harnois ; G. Marcotte ; T. Di PaoloDifferent sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence
004C02 (1988) Thomas L. Perry [Canada] ; Karen Jones [Canada] ; Shirley Hansen [Canada] ; Richard A. Wall [Canada]2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease
004E99 (1986) T. Di Paolo ; P. Bedard ; M. Daigle ; R. BoucherLong-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Catécholamine" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Catécholamine" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Catécholamine
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022